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Abstract
Background: It has been previously shown that enveloped viruses can be inactivated using aryl azides, such as 1-
iodo-5-azidonaphthalene (INA), plus UVA irradiation with preservation of surface epitopes in the inactivated virus
preparations. Prolonged UVA irradiation in the presence of INA results in ROS-species formation, which in turn
results in detergent resistant viral protein fractions.
Results: Herein, we characterize the applicability of this technique to inactivate influenza. It is shown that influenza
virus + INA (100 micromolar) + UVA irradiation for 30 minutes results in a significant (p < 0.05) increase in
pelletablehemagglutinin after Triton X-100 treatment followed by ultracentrifugation. Additionally, characterization
of the virus suspension by immunogold labeling in cryo-EM, and viral pellet characterization via
immunoprecipitation with a neutralizing antibody, shows preservation of neutralization epitopes after this
treatment.
Conclusion: These orthogonally inactivated viral preparations with detergent resistant fractions are being explored
as a novel route for safe, effective inactivated vaccines generated from a variety of enveloped viruses.
Keywords: Influenza virus, Detergent, Detergent resistance, Hemagglutinin, Triton, Vaccine, Inactivation, Human
immunodeficiency virus, HIV-1, Orthogonal
Background
Universal techniques for ther a p i dg e n e r a t i o no fs a f e ,
effective vaccines from a variety of viruses are needed to
protect against a host of diseases. Inactivated virus vac-
cines, which start with infectious material, can be pro-
duced through routes such as chemical inactivation.
These types of vaccines are currently being used (such
as in the USA for Influenza), but continue to have lim-
itations, such as the inability to cross-react between
viral strains and subtypes. For emerging or ill-character-
ized novel pathogens, inactivated vaccines raise the ser-
ious concern of safety. It is generally agreed that the
required inactivation of virus for use in such vaccines is
at least 15 logs of inactivation [1]. Such a high level of
inactivation is difficult to determine, and usually relies
on the use of the combination of techniques for safe
inactivation. These techniques typically operate on
mechanisms independent of one another, and are con-
sidered “orthogonal” inactivation steps. It is generally
accepted that the additive effect of these steps is used
towards the “15 logs” of inactivation suggested for the
generation of a safe vaccine.
One typical method for orthogonal inactivation, is the
generation of “split virus” vaccines. These types of vac-
cines, currently used in some influenza preparations,
rely on chemical means for the initial inactivation of the
virus, followed by detergent treatment to “split” or solu-
bilize the virus. This solubilized viral protein preparation
is then further purified to obtain a specific protein
(hemagglutinin in the case of influenza). This purified
protein only represents a fraction of the overall native
virion, and has been removed from its native environ-
ment in the viral membrane. * Correspondence: blumenthalr@mail.nih.govc
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apply orthogonal inactivation techniques (ie chemical
inactivation + detergent) for safety, but maintain the
epitopes that represent the native virion in order to eli-
cit a more effective immune response similar to whole
virus vaccines [2]. Additionally, such an idealized vac-
cine candidate could be imagined to contain preserved
epitopes that expose functionally conserved regions for
the generation of cross-reactive neutralizing antibodies
[3]. In the context of a “split virus” vaccine, if the che-
mically inactivated virus was partially detergent resistant
before the detergent treatment step, then the detergent
treatment step would serve solely to mop-up any live
viruses, while leaving the inactivated virus similar to the
native virion. Subsequent purification could then be
used to isolate the intact inactivated virus instead of
solubilized proteins.
One way to achieve this is to use a chemical inactivat-
ing agent that is specific to the hydrophobic region of
the bilayer membrane in enveloped viruses, namely 1-
iodo-5-azidonaphthalene (INA) [4]. This hydrophobic
probe, when activated by UVA irradiation for 2-5 min-
utes, results in the inactivation of a variety of enveloped
viruses with preservation of surface epitopes [5-9]. Addi-
tionally, in the case of HIV-1, it was found that pro-
longed UVA irradiation (15 minutes) in the presence of
INA resulted in reactive oxygen species (ROS) genera-
tion, that caused detergent resistance of various viral
proteins, with the preservation of epitopes recognized by
neutralizing antibodies [8,10]. These detergent resistant
fractions were thought to contain fragments of virus
similar to the native virion, and not completely solubi-
lized proteins.
This technique can potentially be applied to a variety
of enveloped viruses for the production of safe inacti-
vated vaccines that are orthogonally inactivated and
contain viral fragments similar to the native virus.
Herein, we explore the applicability of this technique to
the inactivation of influenza virus, with particular atten-
tion to the characterization of the detergent resistant
fraction and the preservation of neutralization epitopes.
This is a necessary step towards the demonstration of
this novel approach as a “universal” and safe method for
the generation of inactivated envelope virus vaccines.
Results and discussion
It has been previously shown that the treatment of
enveloped viruses with aryl azides and minimal UVA
irradiation (for 2 minutes) results in complete viral inac-
tivation due to covalent binding of the hydrophobic
azido compound within the bilayer of enveloped viruses
[5-9]. These inactivated virus preparations have shown
to be effective as vaccine candidates in animal studies
[5,6]. More recently, we have shown that with prolonged
UVA irradiation (15 min irradiation time) in the pre-
sence of aryl-azido compounds, protein aggregates can
be induced in HIV-1, an enveloped virus, as a result of
reactive oxygen species formation [8]. This ROS-modifi-
cation has been shown to induce detergent resistance in
key viral proteins, which makes this treatment applicable
towards the generation of a novel type of orthogonally
inactivated vaccine strategy [10].
Here, we extend this finding to another enveloped
virus, influenza, to show the “universal” and general nat-
ure of this method to treat different enveloped viruses.
We show that for two different strains of Influenza A
virus, X31 (an H3N2 virus) and PR8 (an H1N1 virus), a
similar trend of inactivation and detergent resistance is
seen, characterized herein using Western blot, ultracen-
trifugation, MDCK plaque assays, hemagglutination
assay, immunoprecipitation, and cryo-electron
microscopy.
Treatment of influenza with INA plus prolonged UVA
irradiation results in viral protein aggregation and
minimal effect on hemagglutination
Similar to previous results as seen with HIV [10], it was
found that the viral proteins of the influenza virus can
be modified via reactive oxygen species (ROS) induced
as a by-product of prolonged UVA irradiation in the
presence of an aryl azide. Consistent with the previous
findings for HIV, the transmembrane protein of Influ-
enza (HA2) forms aggregates upon aryl-azide + UVA
treatment, whereas the external proteins (HA1 in influ-
enza) remain largely unaffected (see Figure 1). This
amount of aggregation is increased when the samples
were treated with UVA irradiation for 30 minutes versus
15 minutes.
In contrast with previous findings (with HIV capsid
protein), the solubility of the nucleoprotein (NP) of
influenza virus remains unaffected by ROS species, and
Western blot shows only the main NP band (no protein
aggregates). The nucleoprotein antibody used was cross-
reactive to both strains, and shows that both strains of
influenza tested do not exhibit ROS-induced NP protein
aggregation, as seen in Figure 1. This may be due to the
nature of the nucleoprotein and its assembly in the viral
core. The nucleoprotein inter- or intra- protein interac-
tions may be such that the ROS species are unable to
penetrate and modify the proteins, or it is possible that
the chemical product responsible for the ROS genera-
tion (from the prolonged irradiation of the aryl azide)
may not penetrate these proteins. This hypothesis is
further supported by the detergent treatment experi-
ments described in the next section, and is further ela-
borated therein.
In addition to this Western blot analysis, the ability of
the virus to agglutinate red blood cells was tested before
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1. This assay indicates that the hemagglutinin (HA) pro-
tein located on the surface of the influenza maintains its
ability to establish a binding network that prevents the
settling of the RBC’s even after treatment with pro-
longed UVA irradiation in the presence of INA. While
there is some damage as indicated by the fold reduction
in HAU titer for INA treatments after UVA irradiation
for 15 and 30 min., the virus still maintains the ability
to agglutinate red blood cells, albeit at lower dilutions.
Viral proteins exhibit detergent resistance
It has been previously shown that INA treatment of
influenza and other enveloped viruses results in viral
inactivation after 2-5 minutes of irradiation [5-9] and
therefore prolonged UVA irradiation to induce ROS
species is not necessary for viral inactivation. Addition-
ally, according to Table 1 above, the ability of the influ-
enza virus to agglutinate red blood cells is also
maintained after this brief treatment to inactivate the
virus. However, the protein aggregation that is seen via
Western blot as a result of prolonged irradiation (UVA
irradiation of 15 minutes or more) has been shown to
correlate with detergent resistance in another enveloped
virus, HIV-1 [10]. This “detergent resistance” is being
explored as a novel method for the preparation of an
orthogonally inactivated virus vaccine using aryl azides
and detergent treatment, as initially proposed for HIV.
To this end, the induced “detergent resistance” of two
viral proteins in influenza was studied: HA2 protein (the
transmembrane unit of hemagglutinin) and NP (nucleo-
protein, an internal protein in the virus). Detergent
resistance here is defined as the inability to solubilize a
viral protein after treatment with either 0.5% or 1% Tri-
ton X-100. This can be quantified via ultracentrifugation
through a sucrose pad, and analyzing the amount of pel-
letable viral protein via Western blot (as described in
Materials and Methods). The results are summarized in
Figure 2 below, where an increase in the “% protein in
pellet”, signifies an increase in the “detergent resistant”
fraction.
One major difference between the detergent resistance
seen here for influenza, versus HIV-1, is the irradiation
time required to exhibit detergent resistance. It can be
seen in Figure 2a, for the influenza viral protein, HA2,
that when the irradiation time is increased from 15 min-
utes to 30 minutes in the presence of INA, that the
amount of protein aggregation significantly increases, as
Figure 1 Influenza proteins as visualized by Western blot after UVA irradiation with and without INA. Two strains of influenza PR8 (H1N1
virus) and X31 (H3N2) were tested with varying treatments as specified in the figure. Western blots were subsequently probed with the antibody
noted, either anti-HA2, anti-HA1 or anti-NP. The anti-NP was cross reactive to both strains, whereas anti-HA2 and anti-HA1 were strain specific.
Note that the UVA samples also contain DMSO added in the same amount needed for the addition of the INA to the INA-treated samples.
Table 1 Results of Hemagglutination assay using X31
after various treatments
Treatment Strain, lot #
ending
Fold reduction in HAU
titer*
Flu + INA + UVA 5
min.
X31, 0627 0
X31, 1203A 0
Flu + INA + UVA 15
min.
X31, 0627 0
X31, 1203A 2
Flu + INA + UVA 30
min.
X31, 0627 4
X31, 1203A 4
Each experiment done in duplicate
*relative to untreated control
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Page 3 of 12Figure 2 Increase in the pelletable fraction of influenza PR8 hemagglutinin (HA2) after treatment of virus with INA + UVA irradiation.
a) side-by-side comparison of the raw data used to determine percent HA2 in pellet showing an increase in the pelletable main band as seen
by eye, where A = untreated influenza, B = influenza + INA + UVA 15 min., C = influenza + INA + UVA 30 min., b) quantitation of the
percentage of HA2 in the pelleted fraction after the treatments as specified, c) quantitation of influenza nucleoprotein (NP) in the pelleted
fraction. Data for b) and c) is from the integration of the entire lane in Western blot, except for those labeled “main band only” data, which
represents data obtained from the integration of the main protein band (either HA2 or NP) alone (as outlined in Materials and Methods). All data
was performed in true triplicate, and error bars represent plus and minus two standard deviations. P-values were calculated using a two-tailed
student’s T-test with unequal variances, with significant values (p < 0.05) as denoted below the figure.
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band”) protein. When the amount of influenza viral pro-
tein HA2 was quantified from these and additional Wes-
tern blots, it was seen that the amount of pelletable
protein was increased significantly (p < 0.05) after treat-
ment with 100 micromolar INA + UVA irradiation for
30 minutes, but was not significantly increased with
INA + UVA for 15 minutes, versus UVA irradiation for
30 minutes alone (without INA). Furthermore, the
amount of detergent resistant HA2 was also significantly
increased (p < 0.05) when 30 minutes of UVA irradia-
tion was used (with INA) over the comparable 15 min-
ute treatment. This was shown to hold true for both the
aggregated region of proteins in the Western blot as
well as the non-aggregated ("main band”)p r o t e i n s .
Additionally, it is known that non-ionic detergents such
as Triton X-100, do not readily denature proteins and
have been used to isolate proteins while maintaining
their function [11]. The ability of this treatment to
induce detergent resistance, combined with the “gentle”
nature of non-ionic detergent treatment, is of impor-
tance if this preparation is to be used towards the gen-
eration of a vaccine, with the hypothesis that the viral
protein pellet may better represent the intact proteins of
the native virion.
Interestingly, when the detergent resistance of NP was
studied using the same method after INA treatment +
UVA irradiation for 30 minutes, there was no significant
increase in the pelleted fraction of the influenza viral
protein NP over controls. This finding is in agreement
with the aforementioned Western blot analysis (Figure
1) indicating that there is no protein aggregation of NP
with INA + UVA treatment. Previously, we reported
that there is a correlation between this aggregation as
seen in Western blot with the detergent resistance seen
[10]. Surprisingly, independently of the treatment per-
formed on the virus, 70% of the total NP within the
sample can be pelleted through ultracentrifugation (Fig-
ure 2c). This implies that there is some inherent deter-
gent resistance of the structure adopted by NP within
the influenza virus. It has been shown that proteins can
differ in their solubility by non-ionic detergents (such as
the Triton used herein), with stronger detergents (such
as ionic detergents) needed in order to break stronger
protein-protein interactions [12,13]. It is possible that
the interactions between the nucleoproteins in influenza,
either intra- or inter- NP interactions, are too strong to
be dissociated with Triton X-100. This phenomenon has
been seen before, when Triton X-100 solubilization and
pelleting of influenza infected cells was attempted, only
to find the majority of NP at the bottom of the gradient
[14]. Further characterization of this phenomenon was
not pursued, but is taken as a positive result, since in all
cases there is a significant portion of NP present in the
pellet. The presence of NP in combination with the
HA2 protein in the pellet may be favorable towards the
generation of cross-reactive immune response if this
preparation were to be used in vaccines [3,15].
This finding, with the influenza protein NP (with no
increase in pelletable material), is in contrast to HIV-1,
where an internal viral protein (capsid, p24) showed sig-
nificant protein aggregation and detergent resistance
after INA plus 15 minutes of UVA irradiation [10]. In
the case of HIV, p24 was readily solubilized in Triton
X-100. This is of important note, since this method
(INA + UVA + Triton) is being proposed as a “univer-
sal” method for the orthogonal inactivation of enveloped
viruses with the promotion of detergent resistance.
These results taken together (HA2 and NP for influenza,
gp41 and p24 for HIV-1) suggest that detergent resis-
tance promoted by ROS is applicable to a variety of
enveloped viruses, with the caveat that the nature of the
proteins themselves lends to subtle differences in the
effect of the ROS, and therefore the detergent resistance
profile, throughout the virus.
Influenza inactivation using Triton X-100
While this “INA + prolonged UVA” treatment results in
viral inactivation with detergent resistance, it was
unclear how much of an affect the Triton alone would
be expected to have on viral infectivity. It has been sug-
gested that at least 15 logs of inactivation is needed for
vaccine candidates to be considered safe for use [1].
Towards this requirement, it is widely accepted that
multiple methods of inactivation that operate on
mechanisms independent of one another (ie orthogonal
techniques) can be combined to achieve this suggested
level of inactivation. A recent study [16] found that Tri-
ton can be used to safely inactivate pandemic influenza
for use in BL2 conditions, with the caveat that their
treatment (percent Triton and duration) may not be
directly applicable to all systems, so assessment of Tri-
ton inactivation in our system was warranted. In that
study, they were also required to remove the Triton due
to interference with their cell based assay. Fortuitously,
the influenza strains used herein were highly infectious,
which allowed for inactivation of the purified virus with
Triton, followed by dilution before adding to the cells.
At such high dilutions, there were no cytotoxic effects
on the cells, and plaques could still be counted for the
suboptimal Triton treatments using a cell-based plaque
assay. At concentrations any higher than these, cytotoxic
effects of the MDCK cells were noted (unpublished
observations). For this plaque assay, influenza was trea-
ted with varying percentages of Triton at two different
temperatures. These experiments were performed in
duplicate wells, with the entire experiment reproduced
in true duplicate (or greater) and the values for the log
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information regarding the viral lots used, number of pla-
ques counted at each dilution, etc., is given in Addi-
tional file 1.
In the MDCK assay, the infectivity of the control virus
was determined in plaque-forming units (PFU) and
found to be 10
7.65 PFU/mL and 10
6.56 PFU/mL for the
lot numbers ending in 0627 and 1203A, respectively.
When the control virus was mock-treated at 37°C, along
with the detergent-treated controls (using PBS instead
of Triton X-100), the infectious titer was found to
decrease only slightly to 10
7.15 PFU/mL and 10
6.20 PFU/
mL, respectively. Additional treatments as listed below
in Table 2, show varying logs of inactivation depending
on the Triton percent and temperature used, with the
limit of detection of the assay at 5-6 logs of inactivation.
As shown in Table 2, the amount of Triton needed to
remove at least 5 logs of infectivity (limit of the assay) is
shown to be 0.5% when treatment is done at 37°C. For
almost all the concentrations of Triton X-100 tested, the
number of logs of inactivation increased when the sam-
ples were treated with Triton at 37°C versus at room
temperature. This indicates that the virus is more effi-
ciently solubilized by Triton at higher temperatures,
leading to a higher degree of inactivation.
These results, combined with similar results from
another group [16], indicate that Triton can be used to
successfully inactivate influenza virus. This is of impor-
tant note when considering Triton (or potentially other
non-ionic detergents) for their used in orthogonal inac-
tivation techniques to reach a “safe” level of inactivation.
Additionally, the percent Triton required to inactivate
the virus in our study (0.5% Triton at 37°C), when com-
bined with the INA treatment, results in detergent resis-
tant fragments as noted in Figure 2. Therefore, not only
is this a viable method for orthogonal inactivation, it
also results in a preparation that can be pelleted and
enriched in HA and NP proteins through induced deter-
gent resistance (Figure 2). While the entire treated sus-
pension could be used as a vaccine candidate, it may be
more applicable to purify the preparation via ultracentri-
fugation, yielding the detergent resistant viral pellet.
With this in mind, we further characterized the viral
pellet for recognition by known neutralizing antibodies.
Retention of HA neutralization epitopes in the viral
suspension and detergent resistant pellet
To further characterize the detergent resistant viral pellet
and the entire viral suspension after treatment with INA
plus UVA irradiation for 30 minutes, both immunopreci-
pitation and cryo-electron microscopy (cryo-EM) were
performed. To assess the preservation of neutralization
epitopes in the detergent resistant viral pellet, the virus
was treated with INA + UVA for 30 minutes followed by
detergent treatment, and pelleting. The pellet was then
gently resuspended in 1% Triton and immunoprecipi-
tated using an anti-HA antibody that has been shown to
neutralize influenza and to inhibit hemagglutination in a
variety of influenza A subtypes [17,18]. A Western was
then performed on the immunoprecipitated sample using
an antibody against HA2 (see Figure 3).
The amount of pelletable HA2 not only is increased in
pelleting studies (as shown in Figure 2), but also is
s h o w ni nF i g u r e3t ob ep r e s e r v e di nt h ep e l l e ti n
immunoprecipitation studies. The antibody used for IP
was a polyclonal antibody raised against HA, while the
Table 2 Influenza is completely inactivated by INA
treatment and is inactivated to varying degrees by
Triton X-100
Treatment
a (Triton %, Temperature, etc) Logs of inactivation
b
0%, R.T. 0
0
0
0
0%, 37°C 0.36
0
0.33
0.60
0.2%, R.T. 3.43
3.04
0.2%, 37°C 5.56
5.32
5.48
4.91
0.3%, R.T. 3.67
3.30
0.3%, 37°C 5.48
5.30
0.4%, R.T. 3.87
4.13
4.26
0.4%, 37°C 5.48
5.30
0.5%, R.T. 3.88
4.00
0.5%, 37°C 5.48
5.30
0%, RT, +INA (100 uM, UVA = 5 min.) 5.56
4.56
Duration of Triton treatment was 1 hour with periodic vortex mixing, before
dilution and addition to MDCK cells for a plaque assay. Additional information
is available in supplementary information
aR.T. = room temperature. Only last two entries were INA-treated, as denoted.
bDifference in the number of logs calculated from the room temperature control
for the same lot number, taking into consideration any additional dilution
effects. The limit of detection of the assay is between 5 and 6 logs of inactivation
depending on the viral lot used
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cally against the transmembrane protein HA2. In Figure
2, the pellet obtained for the control sample (flu + Tri-
ton alone) did not contain any intact HA as recognized
by the IP experiment. Conversely, the sample pelleted
after INA + UVA irradiation still contained recognizable
hemagglutinin not only in the main band, but also in
protein aggregates of higher molecular weight.
To ascertain what was happening in the entire treated
viral suspension itself after these various treatments,
cryo-EM was performed. Cryo-EM allowed for visualiza-
tion of the viral suspension in its “native” state, without
the necessity for pelleting and probing through multi-
step microbiological techniques (ie IP and Western
blot). The influenza virus itself (untreated) is studded
with hemagglutinin protein spikes, making it easy to dis-
tinguish in cryo-EM (see Figure 4a). After INA treat-
ment (flu + INA + UVA for 30 minutes), the general
morphology of the influenza virus is maintained, with
HA spikes still visible (Figure 4b). When the INA-trea-
ted sample is subjected to Triton X-100 (0.5%), however,
the resulting suspension contains large viral aggregates
that are not easily identifiable by cryo-EM as individual
virions (Figure 4c). It appears that the viral membrane is
disrupted by Triton treatment and therefore does not
provide the sharp contrast needed in cryo-EM to see the
HA spikes and general “round” nature of the virus.
Interestingly, these viral aggregates are not seen in the
detergent-treated control samples (flu + Triton alone,
data not shown) where INA + UVA irradiation was not
used, indicating here again that the INA treatment of
the virus provides some detergent resistance in the viral
suspension. To further probe the nature of these viral
aggregates in cryo-EM, immunogold labeling studies
were performed using an anti-HA antibody known to
neutralize the virus [17,18]. These aggregates were
shown to contain the antibody labeled proteins from the
labeled virus (Figure 4d), which indicates that the aggre-
gates contain influenza proteins, and potentially frag-
ments of intact virus. An additional control showed that
the binding of the immunogold was not due to non-spe-
cific interactions of the secondary antibody (Figure 4e).
This image also shows that the aggregates are in focus,
as noted by the sole immunogold particle located out-
side the boundary of the aggregate.
Both the IP data and cryo-EM data combined indicate
that after Triton treatment, epitopes that are recognized
by neutralizing anti-HA antibodies are still intact.
Furthermore, the treatment results in a detergent resis-
tant fraction, which when visualized by cryo-EM,
appears as an aggregate of proteins. Since the mem-
branes appear damaged and these clumps have a high
electron density, it is uncertain whether these aggregates
are clumps of virions missing portions of their mem-
branes, such as lipids, (therefore the sharp contrast in
electron density is no longer present) or if they are
aggregates of pieces of the virus. With either scenario,
the end result is that the viral proteins exhibit noticeable
differences in their solubility after Triton treatment
when INA + UVA irradiation is used versus control.
This difference in solubility can be used towards the
generation of a novel orthogonally inactivated vaccine
strategy [10].
Conclusions
In conclusion, we have shown that influenza virus can
be successfully inactivated using both INA + UVA treat-
ment and detergent treatment (Triton X-100). Addition-
ally, with prolonged UVA irradiation (30 minutes) of
influenza in the presence of INA, there is an increase in
the detergent resistant (pelletable) fraction of the trans-
membrane protein HA2, with preservation of neutraliza-
tion epitopes as characterize by immunoprecipitation
and cryo-EM studies. All this, combined with previous
results for HIV-1, indicate that our novel method for
orthogonal inactivation with detergent resistance offers
Figure 3 INA-treatment results in an increase in
pelletablehemagglutinin recognized by neutralizing antibodies.
Influenza virus (PR8) was treated as indicated below the figure.
“Controls” refers to virus after the treatment specified (not
immunoprecipitated). “Immunoprecipitated samples”, as indicated,
were treated as specified and then pelleted through sucrose. All
pellets were then resuspended in 1% Triton and
immunoprecipitated using an anti-HA antibody. Mock-IP was also
performed without the addition of antibody to assess background
binding to the beads. Western blot was probed using anti-HA2.
Image shown is representative of duplicate experiments.
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eration of a new class of inactivated vaccines [10].
Further studies are needed to expand this method to
other viruses and to in vivo studies to assess the effec-
tiveness of these viral preparations versus the standard
split virus vaccines.
Materials and methods
Reagents and cells
1,5-iodonaphthylazide (INA) was custom-synthesized by
Biotium (Hayward, CA). Influenza stocks (for X31 and
PR8 virus) were obtained from Charles River Labora-
tories (CRL) with the strains and lot numbers as speci-
fied in each method below. The following reagents were
obtained through the NIH Biodefense and Emerging
Infections Research Resources Repository ("BEI
resources”), NIAID, NIH: Monoclonal Anti-Influenza A
Virus HA2, Clone RA5-22 (produced in vitro), NR-4539
("anti-HA2”); Polyclonal Anti-Influenza Virus H1 (H0)
Hemagglutinin (HA), A/Puerto Rico/8/34 (H1N1), (anti-
serum, Goat), NR-3148 ("goat anti-HA”, used in immu-
noprecipitation studies). The mouse anti-nucleoprotein
("anti-NP”, A/New Caledonia/20/99, H1N1) antibody
was purchased from eEnzyme (cat# MIA-NP-108). The
mouse anti-HA tag antibody (cat# ab16918, recognizes a
sequence in hemagglutinin from X31 virus and not PR8)
was purchased from AbCam. Secondary antibody used
for Western blot analysis was Alexafluor680 goat anti-
mouse IgG (Invitrogen). Triton X-100 (Surfact-Amps,
ampules of 10% solution in water, cat#PI-28314) was
used for the detergent treatment of viruses. Sucrose
(RNase-free, cat#S9378) was obtained from Sigma-
Aldrich. Madin Darby Canine Kidney (MDCK) cells
were obtained from the American Type Culture Collec-
tion (ATCC, cat # CCL-34), and were grown in MEM
(ATCC, cat# 30-2003) containing 10% heat-inactivated
fetal bovine serum (FBS, Invitrogen). TPCK-trypsin,
used for the MDCK assay, was purchased from Pierce
Figure 4 Cryo-electron microscopy shows intact virions after INA treatment and recognizable hemagglutinin epitopes following Triton
treatment. Influenza (PR8) suspensions were treated with INA + UVA for 30 minutes, then treated with 0.5% Triton X-100 for 1 hour, then fixed
and frozen for cryo-EM. (a) control influenza, (b)influenza + INA + UVA for 30 minutes, (c) “b” plus Triton, (d)immunogold labeling of virus + INA
+ UVA + Triton, (e) Control immunogold sample same as “d” without primary antibody to assess non-specific binding of secondary
immunogold. White lines are drawn to guide the eye in panels “c”, “d” and “e”, indicating the approximate boundary between the aggregated
viral proteins and the bare grid. Arrows indicate immunogold location, in panel “d” within the aggregate, and panel “e” outside the aggregate.
Images shown are representative of sections of overall grid.
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(cat#100.03D) were purchased from Invitrogen, and pro-
tease inhibitor cocktail tablets (Complete Mini Protease
Inhibitor, cat#11836170001) were purchased from Roche
Applied Science. Avicel
® microcrystalline cellulose (RC-
581) used for the MDCK plaque assay was kindly pro-
vided by FMC Biopolymer (Newark, DE).
INA and detergent treatment of influenza
The Influenza used for the detergent treatment studies
was purified Influenza A/PR/8/34 (PR8, H1N1) virus
purchased from Charles River Laboratories (CRL),
cat#10100374, 2 mg/mL total protein, batch#4XP100812
(lot tested by CRL and had an HA titer of 1:65,536 per
0.05 mL, and an egg infectious dose (EID50) of 10
9.5/
mL). The concentrated stock (2 mg/mL total protein)
was thawed at room temperature and handled on ice
immediately following thawing. The stock was diluted to
0.5 mg/mL total protein in PBS and treated with 100
micromolar INA according to similar published proce-
dures [8,10]. In brief, INA was added from a 8 mM
stock solution in DMSO for a final concentration of 100
micromolar in the flu suspension. The suspension was
vortexed briefly and UVA irradiated for either 15 or 30
minutes, as specified in the results section.
For samples requiring subsequent detergent treatment,
T r i t o nX - 1 0 0w a sa d d e d( 1 0u L )f r o m1 0 xT r i t o ns t o c k
solutions added to the flu suspension (90 uL) for the
final percent Triton as specified. Detergent treated sam-
ples were incubated at either room temperature (for
MDCK infectivity studies only) or 37°C (MDCK and
sucrose cushion pelleting studies) for one hour with vor-
tex mixing every 15 minutes.
Plaque assay for detergent-treated influenza
The influenza used for the MDCK assay was purified
Influenza A/Aichi/68 (X31, H3N2) virus purchased from
Charles River Laboratories (CRL), cat#490715, 2 mg/mL
total protein, lots#4XAAH080627 and lot#4-
XAAH021203A. The lot number ending in 0627 was
tested by CRL and had an HA titer of 1:4,194,304 per
0.05 mL, and an egg infectious dose (EID50) of 10
9.7/
mL. The lot number ending in 1203A had an HA titer
of 1:16,384 per 0.05 mL, and an egg infectious dose
(EID50) of 10
6.7/mL.
The influenza was diluted to 0.5 mg/mL total protein
in PBS just prior to detergent treatment. Any remaining
stock was refrozen at -80°C at the original 2 mg/mL
concentration.
Subsequent experiments with the remaining 2 mg/mL
stock was considered to have gone through one “freeze/
thaw” cycle and are labeled as such in the text. Stock
solutions (10x) of triton X-100 were made in PBS; for
example 2% stock was made and used for a final
dilution of 0.2% triton in the viral suspension. To 180
microliters of the 0.5 mg/mL viral suspension was
added 20 microliters of the appropriate 10x Triton
stock. The samples either sat at room temperature or
were placed into a 37°C incubator for 1 hour, with vor-
tex mixing every 10 minutes to prevent settling of the
virus suspension. After 1 hour, all samples were held at
room temperature during dilution and addition to the
plates containing the MDCK cells.
A plaque assay was used to determine the infectivity
of influenza before and after detergent treatment. The
assay was performed according to previously published
procedures, using and Avicel overlay method [19,20]. In
brief, MDCK cells were grown to confluency in 12-well
plates. After washing the growth media (MEM with 10%
FBS) from the cells using PBS, virus (either detergent-
treated or control) was added to duplicate wells in
MEM (without FBS) with TPCK-trypsin in a total
volume of 300 microliters per well. Dilutions of 10
-1 and
10
-2 of the detergent-treated virus suspensions were
added to the appropriate wells on the plate, and 10
-4 to
10
-7 dilutions were added for the controls. In the case
where 0.3% - 0.5% Triton X-100 was used to treat the
virus, either 10
-2 to 10
-3 were plated instead, or the
initial detergent-treated stock was diluted by a factor of
two in MEM without FBS, to overcome the toxicity of
the residual Triton to the cells. These modifications to
the dilutions were accounted for in the calculations of
plaque-forming units (PFU/mL) used to determine the
log reduction in infectivity after detergent treatment.
After adding the samples to the wells, the plates were
incubated at 37°C for 1 hour. Subsequently, the media
was removed and was replaced with fresh media con-
taining MEM, HEPES, TPCK-trypsin, and 1.2% Avicel,
and plates were incubated at 37°C for 48 hours. After
incubation, the media and Avicel overlay were removed
and each well was gently washed with PBS to remove
residual Avicel. Cells were fixed using 70% Ethanol and
stained using crystal violet to visualize the plaques as
regions of missing cells on a lawn of purple-stained
cells.
Hemagglutination assay
Hemagglutination assay was performed according to
previously published procedures [19]. Two separate lots
of X31 virus were tested; CRL lot numbers ending in
-0627 and -1203A as were used for the MDCK plaque
assay described above. In brief, red blood cells were pur-
ified via centrifugation from human blood that was col-
lected from donors in sodium citrate tubes. Isolated red
blood cells (RBC’s) were suspended for a final concen-
tration of ~1% in phosphate buffered saline (PBS). To
each well in a v-bottom 96-well plate was added 50
microliters of virus (control or INA (100 micromolar) +
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To each well was then added 50 uL of 1% human
RBC’s. Plate was gently agitated to mix contents and
allowed to sit for one hour at room temperature before
reading. The hemagglutination unit (HAU) titer was
determined from the highest dilution that showed
hemagglutination (where the RBC’s were held in solu-
tion by the virus).
Sucrose cushion and pelleting of detergent-treated virus
with western blot analysis
Both detergent-treated and control samples were ultra-
centrifuged through a sucrose cushion to separate out
the soluble and insoluble fractions, and analyzed similar
to previously published procedures [10]. 200 uL of 30%
sucrose (in PBS, verified using a Bausch and Lomb
refractometer) was placed into a polycarbonate ultracen-
trifuge tube (Beckman #343776, 8 mm × 34 mm). To
this, 90 uL of detergent-treated flu sample was carefully
added (undiluted) on top of the sucrose cushion with
caution to maintain the phase boundary. The samples
were then ultracentrifuged (Optima TLX tabletop ultra-
centrifuge) in a fixed-angle rotor (TLA 120.1) at 58,000
rpm for one hour at 4°C. Immediately after centrifuga-
tion, the supernatant (290 uL total) was carefully
removed and added to Laemmli reducing sample buffer
in a microfuge tube. To the remaining pellet, still in the
centrifuge tube, was added 290 uL of PBS and sample
buffer. Pellets were very sticky after centrifugation so
care was needed to resuspend them in the sample buffer
by aspirating gently with a pipette tip and pipettor. The
entire centrifuge tube, with pellet solution, was placed
into a larger 2 mL microfuge tube with a lid. The sam-
ples were heated at 70°C for 15-20 minutes and SDS-
PAGE under denaturing and reducing conditions was
r u n( I n v i t r o g e n ,T r i s - g l y c i n eg e l s ,1 0 - w e l l ,4 - 2 0 % ) .T h e
gels were blotted onto nitrocellulose and probed via
Western blot using MAbs for the proteins of interest,
a n dA l e x a f l u o r6 8 0c o n j u g a t e dM o u s eI g Gs e c o n d a r y
antibody for IR readout and integration using an Odys-
sey imaging system and software. Separate lanes for the
pellet (P) solution and supernatant (S) solution were run
for each sample. Integration of each of these lanes was
done using the Odyssey software and each lane was
selected to determine the raw integrated intensity of the
entire lane. The entire lane was selected to include all
the protein aggregates that contained the probed protein
of interest, and the entire lanes were integrated in the
controls as well for direct comparison. The “percent in
pellet” (%P) was then determined using these raw inte-
grated intensities as follows: %P = P/(P + S), where P
and S are the respective integrations of the pellet and
supernatant lanes for one sample. Separate gels were
run for each protein; gels were not reprobed. Each
treatment was triplicate via three separate experiments
starting with fresh viral stock each time. P-values were
calculated using these triplicate in a two-tailed student’s
T-test with unequal variances, with significant values (P
< 0.05).
Immunoprecipitation of pelleted influenza proteins
For immunoprecipitation studies, the purified influenza
virus stock from CRL was influenza A/PR/8/34 (PR8,
H1N1), cat#10100374, 2 mg/mL total protein,
batch#4XP110510 (lot tested by CRL and had an HA
titer of 1:1,048,576 per 0.05 mL, and an egg infectious
dose (EID50) of 10
10.0/mL). Influenza samples were
diluted to 0.5 mg/mL in PBS, treated with INA (100
micromolar) plus UVA for 30 minutes, treated with
detergent (37°C for 1 hour with vortex mixing every 15
minutes) and pelleted thru sucrose as specified above.
Mock-treated (detergent only) samples were also pre-
pared in similar fashion. For immunoprecipitation stu-
dies, the supernatant was discarded and 90 uL of 1%
Triton X-100 in PBS with protease inhibitors was added
to the pellet. The pellet was gently resuspended, trans-
ferred to a microfuge tube, and 10 microliters of Goat
anti-HA antibody (BEI resources) was added to each
sample. Samples were incubated overnight with rotation
at room temperature, covered from light. The following
morning, Dynabeads (prewashed in two volumes of 1%
Triton X-100 in PBS) were added (33.3 uL) to each
sample. Samples were rotated again at room tempera-
ture for 45 minutes. A magnet was applied, supernatant
was removed and beads were washed with 2 volumes of
1% Triton X-100 in PBS (with protease inhibitor) and
two volumes of PBS, with resuspension of the beads and
magnet application between washing steps. After the
final wash, the beds were transferred to a new microfuge
tube, a magnet was applied, PBS was removed, and 60
uL of 1x Laemmli sample buffer (reducing) was added
to each sample. The samples were heated at 70°C for
15-20 minutes and SDS-PAGE under denaturing and
reducing conditions was run (Invitrogen, Tris-glycine
gels, 15-well, 4-20%). The gels were blotted onto nitro-
cellulose and probed via Western blot using mouse anti-
HA2 antibody (BEI resources), and Alexafluor 680 con-
jugated Mouse IgG secondary antibody for IR readout
and integration using an Odyssey imaging system and
software.
Cryo-transmission electron microscopy analysis
For non-immunogold EM studies, the influenza viral lot
ending in #812 from CRL was used. For the immuno-
gold EM studies, the purifiedP R 8i n f l u e n z av i r u ss t o c k
from CRL batch#4XP110510 was used. Influenza stocks
were diluted to 0.5 mg/ml total protein in PBS. Half was
treated with INA (100 micromolar, as previously
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remainder was left untreated as a control. For the
immunogold labeled samples: to 100 uL of each was
added a 1:25 dilution of primary antibody (BEI resources
goat antiserum, anti-H0) and samples were incubated
for 1 hour at room temperature. Control samples were
also prepared that omitted the primary antibody and
used PBS in its place to assess for non-specific adsorp-
tion of the secondary immunogold antibody. Following
this incubation, samples (90 uL) were pelleted through a
200 uL 30% sucrose pad (as described above). Pellets
were gently resuspended in 90 uL of 1 molar HEPES
buffer, transferred to a fresh microfuge tube to which 10
uL of either Triton X-100 (5%) or PBS was added, for a
final detergent concentration of 0.5% and 0% respec-
tively. Microfuge tubes were incubated at 37°C for 1
hour with vortexing at t = 0, 30 min and 1 hour. After
1 hour, 10 microliters of secondary immunogold anti-
body (15 nm rabbit anti-goat IgG, Aurion) was added to
all samples, and incubated at room temperature for an
additional 30 minutes. Samples were then stored over-
night at 4°C. The following day, fixative (8% formalde-
hyde in 1 M HEPES buffer) was added 1:1 to each
sample 30 minutes prior to freezing the samples on
grids for cryo-EM analysis. For the non-immunogold
samples: influenza was prepared as described with the
omission of the primary, secondary antibody and ultra-
centrifugation steps. For these samples, triton (10 micro-
liters of 10x) was added to the diluted +/- INA-treated
samples (90 microliters) and incubated at 37°C for 1
hour with periodic vortex mixing as described above.
Fixative was added immediately following this incuba-
tion and cryo-EM was performed. For cryo-EM, 4 μLo f
sample were blotted onto glow-discharged holey carbon
grids R2/2 (Quantifoil) and vitrified in a Vitrobotcryos-
tation (FEI). Images were recorded with a T20 micro-
scope (FEI) at 200 kV on an Eagle CCD camera (FEI).
Additional material
Additional file 1: S1 Amount of Triton required to remove
infectious material from Influenza X31 as measured using an MDCK
plaque assay. (expansion of data shown in Table 2 in text).
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